Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $37.56

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given an average rating of “Moderate Buy” by the nineteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $37.56.

Several analysts have weighed in on the stock. Wedbush reissued a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Barclays lowered their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Citigroup raised their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Chardan Capital dropped their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Finally, Oppenheimer cut their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $9.00 on Friday. Intellia Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $28.23. The firm has a market cap of $931.65 million, a price-to-earnings ratio of -1.65 and a beta of 1.97. The firm has a 50 day moving average price of $10.09 and a 200-day moving average price of $14.13.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 29,000 shares of company stock worth $352,551. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics during the fourth quarter valued at $25,000. Sterling Capital Management LLC increased its position in shares of Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics in the 4th quarter worth approximately $40,000. Resona Asset Management Co. Ltd. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $43,000. Finally, KBC Group NV boosted its stake in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.